CNR1 Variation Modulates Risk for Drug and Alcohol Dependence

Biological Psychiatry

Volumn 62, Issue 6, 2007, Pages 616-626

  Zuo, Lingjun ^a,b   Kranzler, Henry R ^c   Luo, Xingguang ^a,b   Covault, Jonathan ^c   Gelernter, Joel ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Alcohol dependence; CNR1; drug dependence; fine mapping; gene gene interaction; substance dependence

Indexed keywords

CANNABINOID 1 RECEPTOR;

ADULT; AFRICAN AMERICAN; AGE DISTRIBUTION; ALCOHOLISM; ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE; EUROPEAN AMERICAN; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK ASSESSMENT; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SUBSTANCE ABUSE;

ADULT; AFRICAN AMERICANS; ALCOHOLISM; CASE-CONTROL STUDIES; CHROMOSOME MAPPING; COMORBIDITY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, CANNABINOID, CB1; REGRESSION ANALYSIS; RISK FACTORS; SUBSTANCE-RELATED DISORDERS; VARIATION (GENETICS);

EID: 34548176584     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2006.12.004     Document Type: Article

References (71)

1. Alger B.E. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol 68 (2002) 247-286
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. (1987), American Psychiatric Press, Washington, DC revised
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (1994), American Psychiatric Press, Washington, DC
4. Ball D.M., and Murray R.M. Genetics of alcohol misuse. Br Med Bull 50 (1994) 18-35
5. Barrett J., Fry B., Maller J., and Daly J. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263-265
6. Bengtsson B.O., and Thomson G. Measuring the strength of associations between HLA antigens and diseases. Tissue Antigens 18 (1981) 356-363
7. Blum K., Cull J.G., Braverman E.R., and Comings D.E. Reward deficiency syndrome. Am Scient 84 (1996) 132-145
8. Burns L., and Teesson M. Alcohol use disorders comorbid with anxiety, depression and drug use disorders. Findings from the Australian National Survey of Mental Health and Well Being. Drug Alcohol Depend 68 (2002) 299-307
9. Chaperon F., Soubrie P., Puech A.J., and Thiebot M.H. Involvement of central cannabinoid (CB1): receptors in the establishment of place conditioning in rats. Psychopharmacology (Berl) 135 (1998) 324-332
10. Chen J., Paredes W., Li J., Smith D., Lowinson J., and Gardner E.L. D9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology (Berl) 102 (1990) 156-162
11. Comings D.E., Muhleman D., Gade R., Johnson P., Verde R., Saucier G., and MacMurray J. Cannabinoid receptor gene (CNR1): Association with i.v. drug use. Mol Psychiatry 2 (1997) 161-168
12. Cossu G., Ledent C., Fattore L., Imperato A., Bohme G.A., Parmentier M., et al. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behav Brain Res 118 (2001) 61-65
13. Covault J., Gelernter J., and Kranzler H. Association study of cannabinoid receptor gene (CNR1) alleles and drug dependence. Mol Psychiatry 6 (2001) 501-502
14. Crabbe J.C., Belknap J.K., and Buck K.J. Genetic animal models of alcohol and drug abuse. Science 264 (1994) 1715-1723
15. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., and Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34 (1988) 605-613
16. Devlin B., and Risch N. A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics 29 (1995) 311-322
17. Di Chiara G. A motivational learning hypothesis of the role of mesolimbic dopamine in compulsive drug use. J Psychopharmacol 12 (1998) 54-67
18. Falush D., Stephens M., and Pritchard J.K. Inference of population structure using multilocus genotype data: Linked loci and correlated allele frequencies. Genetics 164 (2003) 1567-1587
19. George F.R. Genetic models in the study of alcoholism and substance abuse mechanisms. Prog Neuropsychopharmacol Biol Psychiatry 17 (1993) 345-361
20. Giuffrida A., Parsons L.H., Kerr T.M., Rodriguez de Fonseca F., Navarro M., and Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2 (1999) 358-363
21. Gurwitz D., and Kloog Y. Do endogenous cannabinoids contribute to HIV-mediated immune failure. Mol Med Today 4 (1998) 196-200
22. Heller D., Schneider U., Seifert J., Cimander K.F., and Stuhrmann M. The cannabinoid receptor gene (CNR1) affected in German i.v. drug users. Addict Biol 6 (2001) 183-187
23. Herkenham M. Cannabinoid receptor localization in brain: Relationship to motor and reward systems. Ann N Y Acad Sci 654 (1992) 19-32
24. Herman A.I., Kranzler H.R., Cubells J.F., Gelernter J., and Covault J. Association study of the CNR1 gene exon 3 alternative promoter region polymorphisms and substance dependence. Am J Med Genet Part B Neuropsychiatr Genet 141B (2006) 499-503
25. Howlett A.C., Bidaut-Rusell M., Devane W.A., Melvin L.S., Johnson M.R., and Herkenham M. The cannabinoid receptor: Biochemical, anatomical and behavioural characterization. Trends Neurosci 13 (1990) 420-423
26. Hungund B.L., Szakall I., Adam A., Basavarajappa B.S., and Vadasz C. Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J Neurochem 84 (2003) 698-704
27. Karkowski L.M., Prescott C.A., and Kendler K.S. Multivariate assessment of factors influencing illicit substance use in twins from female-female pairs. Am J Med Genet 96 (2000) 665-670
28. Kendler K.S., Jacobson K.C., Prescott C.A., and Neale M.C. Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am J Psychiatry 160 (2003) 687-695
29. Kessler R.C., Berglund P., Demler O., Jin R., Merikangas K.R., and Walters E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62 (2005) 593-602
30. Koob G.F. Drugs of abuse: Anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13 (1992) 177-184
31. Koob G.F., and Bloom F.E. Cellular and molecular mechanisms of drug dependence. Science 242 (1988) 715-723
32. Koob G.F., and Le Moal M. Drug abuse: Hedonic homeostatic dysregulation. Science 278 (1997) 52-58
33. Koob G.F., and Le Moal M. Plasticity of reward neurocircuitry and the "dark side" of drug addition. Nat Neurosci 8 (2005) 1442-1444
34. Le Moal M., and Simon H. Mesocorticolimbic dopaminergic network: Functional and regulatory roles. Physiol Rev 71 (1991) 155-234
35. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J.F., Beslot F., et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283 (1999) 401-404
36. n repeats in the cannabinoid receptor gene (CNR1) and heroin abuse in a Chinese population. Mol Psychiatry 5 (2000) 128-130
37. Liu K, Muse S (2004): PowerMarker: new genetic data analysis software. Version 3.0. Distributed by the author. Available at: http://www.powermarker.net. Accessed June 1, 2006.
38. Luo X., Kranzler H.R., Zuo L., Lappalainen J., Yang B.Z., and Gelernter J. ADH4 gene variation is associated with alcohol dependence and drug dependence in European Americans: Results from HWD tests and case-control association studies. Neuropsychopharmacology 31 (2006) 1085-1095
39. Luo X., Kranzler H.R., Zuo L., Wang S., Lappalainen J., Schork N.J., and Gelernter J. Diplotype trend regression (DTR) analysis of the ADH gene cluster and ALDH2 gene: Multiple significant associations for alcohol dependence. Am J Hum Genet 78 (2006) 973-987
40. Luo X., Kranzler H.R., Zuo L., Yang B.Z., Lappalainen J., and Gelernter J. ADH4 gene variation is associated with alcohol dependence and drug dependence in European Americans: Results from family-controlled and population-structured association studies. Pharmacogenet Genomics 15 (2005) 755-768
41. Lupica C.R., and Riegel A.C. Endocannabinoid release from midbrain dopamine neurons: A potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuropharmacology 48 (2005) 1105-1116
42. Mailleux P., and Vanderhaeghen J.J. Glutamatergic regulation of cannabinoid receptor gene expression in the caudate-putamen. Eur J Pharmacol 266 (1994) 193-196
43. Manzanares J., Corchero J., Romero J., Fernández-Ruiz J.J., Ramos J.A., and Fuentes J.A. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 20 (1999) 287-294
44. Mascia M.S., Obinu M.C., Ledent C., Parmentier M., Bohme G.A., Imperato A., et al. Lack of morphine-induced dopamine release in the nucleus accumbens of cannabinoid CB(1) receptor knockout mice. Eur J Pharmacol 383 (1999) R1-R2
45. Matsuda L.A., Bonner T.I., and Lolait S.J. Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 327 (1993) 535-550
46. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
47. Nyholt D.R. A simple correction for multiple testing for singlenucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 74 (2004) 765-769
48. Ozelius L.J., Kramer P.L., deLeon D., Risch N., Bressman S.B., Breakefield X.O., et al. Strong allelic association between the torsion dystonia gene (DYT1) and loci in chromosome 9q34 in Ashkenazi Jews. Am J Hum Genet 50 (1992) 619-628
49. Ozelius L.J., Teitz S.S., Buckler A., Hervitt J., Gasser T., Breakefield X.O., et al. Fine mapping of the torsion dystonia gene (DYT1) on 9q34 and evaluation of a candidate gene. Am J Hum Genet 51 suppl (1992) A224
50. Parra E.J., Marcini A., Akey J., Martinson J., Batzer M.A., Shriver M.D., et al. Estimating African American admixture proportions by use of population-specific alleles. Am J Hum Genet 63 (1998) 1839-1851
51. Pickens R.W., Svikis D.S., McGue M., and LaBuda M.C. Common genetic mechanisms in alcohol, drug, and mental disorder comorbidity. Drug Alcohol Depend 39 (1995) 129-138
52. Pontieri F.E., Tanda G., Orzi F., and Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382 (1996) 255-257
53. Pritchard J.K., Stephens M., and Donnelly P. Inference of population structure using multilocus genotype data. Genetics 155 (2000) 945-959
54. Pritchard J.K., Stephens M., Rosenberg N.A., and Donnelly P. Association mapping in structured populations. Am J Hum Genet 67 (2000) 170-181
55. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., and Goodwin F.K. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA 264 (1990) 2511-2518
56. Risch N., deLeon D., Ozelius L.J., Kramer P., Almasy L., Bressman S., et al. Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population. Nature Genet 9 (1995) 152-159
57. Sanudo-Pena M.C., Tsou K., and Walker J.M. Motor action of cannabinoids in the basal ganglia output nuclei. Life Sci 65 (1999) 703-713
58. Schmidt L.G., Samochowiec J., Finckh U., Fiszer-Piosik E., Horodnicki J., Hoehe M.R., et al. Association of a cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. Drug Alcohol Depend 65 (2002) 221-224
59. Shi M.M., Myrand S.P., Bleavins M.R., and de la Iglesia F.A. High throughput genotyping for the detection of a single nucleotide polymorphism in NAD(P)H quinone oxidoreductase (DT diaphorase) using TaqMan probes. Mol Pathol 52 (1999) 295-299
60. Sieradzan K.A., Fox S.H., Hill M., Disck J.P., Crossman A.R., Brotchie J.M., et al. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: A pilot study. Neurology 57 (2001) 2108-2111
61. Spitzer R.L., and Endicott J. Schedule for affective disorders and schizophrenia: Lifetime version (1975), New York Biometrics Research Division, New York State Psychiatric Institute, New York
62. Stephens M., and Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73 (2003) 1162-1169
63. Tanda G., Pontieri F.E., and Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common m1 opioid receptor mechanism. Science 276 (1997) 2048-2050
64. Tsuang M.T., Lyons M.J., Meyer J.M., Doyle T., Eisen S.A., Eaves L., et al. Co-occurrence of abuse of different drugs in men; the role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry 55 (1998) 967-972
65. Tsou K., Brown S., Sanudo-Pena M.C., Mackie K., and Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83 (1998) 393-411
66. Tsuneyuke Y., and Kohji T. Role of cannabinoid receptor in the brain as it relates to drug reward. J. Pharmacol 84 (2000) 229-236
67. Wise R.A., and Rompre P.P. Brain dopamine and reward. Annu Rev Psychol 40 (1989) 191-225
68. Yang B.Z., Zhao H., Kranzler H.R., and Gelernter J. Practical population group assignment with selected informative markers: Characteristics and properties of Bayesian clustering via STRUCTURE. Genet Epidemiol 28 (2005) 302-312
69. Zaykin D.V., Westfall P.H., Young S.S., Karnoub M.C., Wagner M.J., and Ehm M.G. Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. Hum. Hered 53 (2002) 79-91
70. Zhang P.W., Ishiguro H., Ohtsuki T., Hess J., Carillo F., Uhl G.R., et al. Human cannabinoid receptor 1: 5′ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry 9 (2004) 916-931
71. Zuo L., Van Dyck C.H., Luo X., Kranzler H.R., Yang B.Z., and Gelernter J. Variation at APOE and STH loci and Alzheimer's disease. Behav Brain Funct 2 (2006) 13